HP settles investors' lawsuit over Autonomy deal, say reports

Guardian (UK) |

Hewlett-Packard and lawyers representing its shareholders have agreed to settle litigation over its troubled $11.1bn acquisition of software company Autonomy, according to a source familiar with the negotiations. Under the terms of the settlement, involving three lawsuits, lawyers for the shareholders have agreed to drop all claims against HP's current and former executives, including chief executive Meg Whitman, board members and advisers to the company, the source said. The exception to that will be former officials at Autonomy. As part of the agreement, the shareholders' lawyers will assist HP in pursuing claims against Autonomy's co-founder and former CEO Michael Lynch, its former chief financial officer Sushovan Hussain and potentially others related to Autonomy, the source said. The precise nature of such claims and when HP might file them could not be learned. The company said last night: "HP is in serious discussions to settle the shareholder derivative litigation related to Autonomy, but no final deal has been reached yet." The settlement, which followed mediation, is expected to be announced as soon as Monday. HP took an $8.8bn impairment charge in November 2012 for its purchase of Autonomy just over a year earlier, with more than $5bn of that linked to what HP said at the time were "serious accounting improprieties, misrepresentation and disclosure failures". The size of the loss, and the speed with which it occurred, mark the deal as one of the most disastrous done by a major company in recent years. Sources close to HP's investigation say the technology firm believes Autonomy's results and prospects were made to look much better than they were. Lynch has consistently denied HP's allegations, saying it is blaming him for its own failure to manage Autonomy after the acquisition. A spokesman for Lynch said: "We continue to reject HP's allegations." He said it appeared that Whitman would spend a large amount of HP money to avoid explaining in court why she made the November 2012 allegations about Autonomy. "We hope this matter will now move beyond a smear campaign based on selective disclosure and HP will finally give a full explanation," the spokesman added. Hussain has not responded to calls and emails. His lawyer, John Keker, did not respond to requests for comment. Shareholders had sued HP board members and executives, accusing them of breaching their fiduciary duties and wasting corporate assets. The lawsuits sought corporate governance changes at HP, legal fees and the ability to pursue damages claims against those responsible for the acquisition. HP has shared the results of its investigation into accounting questions at Autonomy with lawyers representing the shareholders, the source familiar with the negotiations said. One of the law firms representing shareholders in the settlement, Robbins Geller Rudman & Dowd, declined to comment. The other firm, Cotchett Pitre & McCarthy, was not immediately available for comment. Lawyers representing shareholders will receive fees for helping HP pursue any further claims, the source said. Additional terms of HP's settlement with shareholders are unclear. HP's allegations of accounting improprieties, misrepresentation and disclosure failures at Autonomy have prompted an investigation by the US securities and exchange commission and the FBI, as well as the Serious Fraud Office. The FBI and SEC declined to comment. The SFO said its inquiry was "very much in progress". Captions: Hewlett-Packard CEO Meg Whitman is among executives said to be spared further legal action under the agreement

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Companies

Symbol Name Price Change % Volume
SNCAF SNC-Lavalin Group Inc 43.40 0.00 0.00 1,000

Comments

Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets

Cross Campus

With over 500 members and operating 80,000 square feet by summer 2016, Cross Campus is one of the country’s top ten shared, collaborative office or "coworking" operators in the US.…

Initial State

Initial State is an Internet of Things (IoT) data analytics & data management platform company. We turn sensor and event data into information that matters by making it easy to…